Publication | Closed Access

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

First-line Maintenance TherapyMedicinePathologyImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung Cancer